Skip to main content

Table 2 Summary of the multivariable analyses of prognostic factors

From: Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis

Variable OS DSS DMFS LRFS
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
IC regimen (PF vs. TPF) 0.660 (0.442–0.986) 0.042 0.624 (0.411–0.947) 0.027 0.589 (0.406–0.855) 0.005 1.213 (0.719–2.047) 0.469
Gender (male vs. female) 0.812 (0.581–1.135) 0.223 0.727 (0.510–1.037) 0.079 0.918 (0.640–1.317) 0.643 0.649 (0.381–1.106) 0.112
Age 1.027 (1.016–1.039) 0.001 1.024 (1.012–1.036) 0.001 1.013 (1.000–1.025) 0.044 1.020 (1.003–1.037) 0.023
Smoking (yes vs. no) 1.041 (0.796–1.363) 0.768 1.003 (0.760–1.323) 0.985 0.944 (0.694–1.285) 0.715 0.976 (0.648–1.472) 0.909
T stage (T1–2 vs. T3–4) 1.393 (1.178–1.648) 0.001 1.231 (0.979–1.549) 0.075 1.306 (1.086–1.570) 0.005 1.420 (1.094–1.842) 0.008
N stage (N0–1 vs. N2–3) 1.308 (1.135–1.509) 0.001 1.177 (1.028–1.349) 0.018 1.547 (1.312–1.824) 0.001 1.146 (0.902–1.456) 0.266
Clinical stage (III vs. IV) 1.185 (0.855–1.642) 0.309 1.630 (1.268–2.097) 0.027 1.012 (0.701–1.460) 0.951 0.909 (0.526–1.572) 0.734
CDDP dose (< 200 mg/m2 vs. ≥ 200 mg/m2) 0.884 (0.695–1.125) 0.316 0.869 (0.676–1.118) 0.276 1.012 (0.772–1.327) 0.930 1.054 (0.728–1.526) 0.782
Number of IC cycles (< 2 cycles vs. ≥ 2 cycles) 1.089 (0.782–1.518) 0.613 1.121 (0.788–1.593) 0.526 1.217 (0.809–1.829) 0.346 0.899 (0.551–1.467) 0.670
Time to RT (< 60 days vs. ≥ 60 days) 0.874 (0.650–1.173) 0.369 0.840 (0.618–1.142) 0.265 1.102 (0.807–1.506) 0.541 0.857 (0.548–1.339) 0.498
Radiation technique (IMRT vs. 2D-CRT) 1.540 (1.134–2.091) 0.006 1.442 (1.053–1.975) 0.022 1.273 (0.914–1.775) 0.153 1.015 (0.654–1.574) 0.948
  1. IC induction chemotherapy, TPF taxane, cisplatin and 5-fluorouracil, PF cisplatin and 5-fluorouracil, CDDP dose the cisplatin dose of concurrent chemotherapy, RT radiotherapy, IMRT intensity-modulated radiotherapy, 2D-CRT two-dimensional radiotherapy, HR hazard ratio